Sector News

Allergan to cut loose 577 more workers in Irvine

April 20, 2015
Life sciences
The pink slips are flying at Allergan once again. Recently bought by Actavis ($ACT) in a $66 billion deal, the company is preparing to lay off 577 more workers in a cost-cutting drive that started last year and won’t end till its new head honchos finish squeezing savings out of the combined company.
 
According to a WARN notice filed with the state of California, Allergan plans to cut loose those 577 staffers in its home city of Irvine. The cuts are set for June 4, the state says in a compendium of layoffs kept on its website.
 
When Allergan was struggling to fend off a $53 billion hostile takeover by Valeant Pharmaceuticals ($VRX), then-CEO David Pyott rolled out a cost-savings plan to appease investors. The company said it would cut 1,500 jobs and other costs to save $475 million this year.
 
Valeant, for its part, said it would slash at least $2.7 billion in annual costs, 80% within the first 6 months.
 
That was July. By November, Allergan had agreed to a $66 billion bid from Actavis, and executives there were talking about $1.8 billion in savings, most of it within the first year. And that would be on top of Allergan’s cost cuts.
 
Since Allergan announced those first cuts, the company has warned the state about 674 layoffs, not including the latest notice. Some 500 of those were to come in Irvine, with the remainder in Carlsbad and Goleta.
 
So, with the latest group of 577, that’s more than 1,000 layoffs in Allergan’s headquarters city.
 
The job cuts in California haven’t spared Actavis’ own operations, however. The company warned the state of 288 layoffs in recent months, the lion’s share in Corona, its headquarters in a previous iteration as Watson Pharmaceuticals. And that’s after a string of job cuts across the country, including 30% of its U.S. sales operation back in 2013.
 
By Tracy Staton
 

comments closed

Related News

January 22, 2023

Sun Pharma to buy Concert Pharmaceuticals for $576m

Life sciences

Sun Pharmaceutical Industries has signed a definitive agreement to buy all outstanding shares of Concert Pharmaceuticals in a deal valued at $576m. Under the deal, the company will buy all shares of Concert common stock through a tender offer for $8.00 per share in cash upfront payment.

January 22, 2023

Novo Nordisk diabetes pill wins FDA approval for first-line use

Life sciences

The Food and Drug Administration on Thursday approved Novo Nordisk’s diabetes pill Rybelsus as an initial treatment to lower blood sugar levels, a label expansion that will allow it to compete more directly with other oral drugs from Merck & Co. and Eli Lilly.

January 22, 2023

Bayer feeling more heat from activist investors, this time from Bluebell

Life sciences

Since making an ill-advised $63 billion buy of Monsanto in 2018, Bayer has faced heaps of pressure from investors that have called for the company to oust its leadership and to restructure. Now comes new pressure from a familiar source. Bluebell Capital Partners has bought an undisclosed stake in the company and is agitating for a breakup, sources told Reuters.

How can we help you?

We're easy to reach